AP3 Impurity 2 is a bioactive molecules.

Diethyl pyimDC is a novel inhibitor of human CP4H1 (collagen prolyl 4-hydroxylase 1). Collagen is the most abundant protein in animals. Its overproduction is associated with fibrosis and cancer metastasis. The stability of collagen relies on post-translational modifications, the most prevalent being the hydroxylation of collagen strands by collagen prolyl 4-hydroxylases (CP4Hs). Catalysis by CP4Hs […]

AZD-0284 is a novel, potent, selective, inverse agonist of the nuclear receptor RORγ. It is in development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders.

Ulevostinag (MK-1454; MK1454) is an investigational small molecule STING agonist with potential immunomodulatory and anticancer activities. It can be administered as an intratumoral injection and is currently being evaluated in a Phase 1 clinical trial for the treatment of solid tumors and lymphomas (ClinicalTrials.gov, NCT03010176). STING is a signaling molecule that plays an important role […]

Obinutuzumab (also called afutuzumab until 2009, originally GA101) is a novel glycoengineered and humanized Type II CD20 monoclonal antibody approved for treating non-Hodgkin lymphoma. Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US […]

Vatinoxan HCl/hydrochloride (also known as MK-467 hydrochloride and L-659066 hydrochloride) is a novel and potent peripheral α2 adrenergic receptor antagonist. MK-467 dose-dependently attenuated the bradycardia associated with dexmedetomidine, and shortened the sedative effect without altering its quality. MK-467 may be useful in attenuating reductions in HR in conscious cats administered dexmedetomidine. MK-467 attenuated or prevented […]

DFMTI is a novel compound that can completely block the rmGlu1 L757V glutamate response by acting as a novel mGlu₁ negative allosteric modulator. Recent progress in the discovery of mGlu₁ allosteric modulators has suggested the modulation of mGlu₁ could offer possible treatment for a number of central nervous system disorders; however, the available chemotypes are […]

2-Hydroxyethyl methacrylate (HEMA) was the first monomer to be used in the synthesis of hydrogels for biomedical applications.The water swelling properties of HEMA are enhanced by copolymerization with more hydrophilic monomers. HEMA has wide applications in drug delivery.

Atezolizumab (also known as MPDL3280A; trade name: Tecentriq) is a novel and selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1). In May 2016 FDA granted accelerated approval to atezolizumab for locally advanced or metastatic urothelial carcinoma treatment after failure of cisplatin-based chemotherapy.[3] The confirmatory trial (to convert the accelerated approval into a […]